A 58-year-old man with primary knee osteoarthritis is counselled about disease management. Which of the following statements regarding osteoarthritis management is NOT correct?

Explanation

## Management Approach to Osteoarthritis **Key Point:** Osteoarthritis management is stepwise and symptomatic, focusing on pain relief and functional improvement. DMARDs are NOT indicated in OA — they are reserved for inflammatory arthropathies like rheumatoid arthritis. OA is a degenerative, non-inflammatory condition that does not respond to disease-modifying therapy. ### Evidence-Based OA Management Hierarchy ```mermaid flowchart TD A[Osteoarthritis diagnosed]:::outcome --> B[Non-pharmacological interventions]:::action B --> C[Weight reduction, exercise, PT]:::action B --> D[Assistive devices, joint protection]:::action C --> E{Adequate symptom control?}:::decision E -->|Yes| F[Continue conservative management]:::action E -->|No| G[Pharmacological therapy]:::action G --> H[Topical/Oral NSAIDs, Acetaminophen]:::action H --> I{Persistent pain?}:::decision I -->|Yes| J[Intra-articular corticosteroids]:::action I -->|No| K[Maintain current regimen]:::action J --> L{Functional improvement?}:::decision L -->|No| M[Consider joint replacement]:::action L -->|Yes| N[Repeat injections as needed]:::action ``` ### Management Components | Intervention | Role in OA | Evidence | |--------------|-----------|----------| | Weight reduction | First-line; reduces joint stress | High-quality evidence | | Physical therapy & exercise | Strengthens muscles, improves function | Recommended by all guidelines | | Topical NSAIDs | Safe for localized pain | Effective with fewer systemic effects | | Oral NSAIDs/Acetaminophen | Pain control in moderate disease | Standard of care | | Intra-articular corticosteroids | Short-term relief (3–6 months) | Symptomatic, not disease-modifying | | Hyaluronic acid injections | Controversial; modest benefit in some | Limited evidence; not universally recommended | | **DMARDs** | **NOT indicated** | **Reserved for inflammatory arthropathies** | | Joint replacement | End-stage disease with failed conservative care | Definitive surgical option | ### Why DMARDs Are Wrong in OA **High-Yield:** DMARDs (methotrexate, biologics, sulfasalazine) target inflammatory pathways and are designed to halt disease progression in inflammatory arthropathies like RA and seronegative spondyloarthropathies. OA is a degenerative, non-inflammatory condition where: 1. Inflammation is secondary and mild, not the primary driver 2. Cartilage loss is mechanical, not immune-mediated 3. DMARDs have no proven benefit in OA 4. Using DMARDs in OA exposes patients to unnecessary toxicity **Clinical Pearl:** The distinction between OA and RA is crucial for treatment selection. A patient with knee OA should never receive methotrexate or TNF inhibitors — these are reserved for inflammatory conditions. **Mnemonic for OA Management (PACE):** - **P**hysical therapy and weight loss (first-line) - **A**nalgesics and topical NSAIDs (pain control) - **C**orticosteroid injections (intra-articular, short-term relief) - **E**nd-stage: joint replacement **Warning:** Confusing OA with RA is a common NEET PG trap. Remember: OA = degenerative, non-inflammatory, no DMARDs. RA = inflammatory, systemic, requires DMARDs.